// App-Quantinova.ai

e18020 : Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib/II trial (N16IMC, NCT03003637).

Researchers

Presenter

  • Charlotte L. Zuur

Principal Investigators

  • Joris B. W. Elbers

  • Anne van der Leun

  • Michiel van den Brekel

  • Bing Tan

  • Bas Jasperse

  • Wouter Vogel

  • Laura Smit

  • Stefan M. Willems

  • Abrahim Al-Mamgani

  • Jasper Nijkamp

  • Ton Schumacher

  • Christian U. Blank

  • J. P. De Boer

  • John B. A. G. Haanen

Medical Centers

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Antoni van Leeuwenhoek - NKI (Netherlands Cancer Institute), Amsterdam, Netherlands

  • Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Antoni van Leeuwenhoek hospital, Amsterdam, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT03003637

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved